Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin HA of the influenza A virus, effectively neutralizing strains H1, H2, H5, and H9 by binding to the HA2 stem fusion domain [1].
CAS Number:
[1443004-16-7]
* VAT and and shipping costs not included. Errors and price changes excepted
